NASDAQ: THRXTheseus Pharmaceuticals Inc Stock
$13.69+0.30 (+2.24%)
Updated Feb 3, 2023
THRX Price
$13.69
Fair Value Price
N/A
Market Cap
$529.99M
52 Week Low
$4.01
52 Week High
$15.21
P/E
0.92x
P/B
2.42x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$45.55M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.05
Operating Cash Flow
-$33M
Beta
1.53
Next Earnings
Mar 9, 2023
Ex-Dividend
N/A
Next Dividend
N/A
THRX Overview
Theseus Pharmaceuticals Incorporated is a biopharmaceutical company that develops cancer treatments. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company's development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. Theseus Pharmaceuticals was incorporated in 2017 and is headquartered in Cambridge, MA.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how THRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
THRX is good value based on its earnings relative to its share price (0.92x), compared to the US market average (15.09x)
P/E vs Market Valuation
THRX is good value based on its earnings relative to its share price (0.92x), compared to the US Biotechnology industry average (10.7x)
P/E vs Industry Valuation
THRX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more THRX due diligence checks available for Premium users.
Be the first to know about important THRX news, forecast changes, insider trades & much more!
THRX News
Valuation
THRX fair value
Fair Value of THRX stock based on Discounted Cash Flow (DCF)
Price
$13.69
Fair Value
$11.03
Overvalued by
24.06%
THRX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0.92x
Industry
10.7x
Market
15.09x
THRX is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
THRX is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
THRX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.42x
Industry
5.11x
THRX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
THRX's financial health
Profit margin
Revenue
$0.0
Net Income
-$14.7M
Profit Margin
0%
THRX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$230.3M
Liabilities
$11.7M
Debt to equity
0.05
THRX's short-term assets ($215.00M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
THRX's short-term assets ($215.00M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
THRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$7.2M
Investing
-$12.3M
Financing
$0.0
THRX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
THRX vs Biotech Stocks
Theseus Pharmaceuticals Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.